Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $583,692.00 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 50,800 shares of the stock in a transaction on Friday, April 11th. The shares were sold at an average price of $11.49, for a total value of $583,692.00. Following the sale, the chief executive officer now owns 3,921,255 shares in the company, valued at approximately $45,055,219.95. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Christopher Richard Anzalone also recently made the following trade(s):

• On Wednesday, April 9th, Christopher Richard Anzalone sold 40,322 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $10.07, for a total transaction of $406,042.54.
• On Thursday, March 13th, Christopher Richard Anzalone sold 51,425 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75.
• On Tuesday, March 4th, Christopher Richard Anzalone sold 133,333 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66.

Arrowhead Pharmaceuticals Trading Up 4.3 %

ARWR traded up $0.53 on Tuesday, reaching $12.87. 1,827,661 shares of the company's stock were exchanged, compared to its average volume of 1,413,277. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The company's 50 day moving average is $15.76 and its 200-day moving average is $18.76. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -2.49 and a beta of 0.99.

Remove Ads

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). Equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ARWR. HighTower Advisors LLC lifted its position in Arrowhead Pharmaceuticals by 11.5% during the 3rd quarter. HighTower Advisors LLC now owns 123,477 shares of the biotechnology company's stock worth $2,401,000 after acquiring an additional 12,706 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 0.9% during the third quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after purchasing an additional 26,171 shares during the period. State Street Corp lifted its position in shares of Arrowhead Pharmaceuticals by 8.8% during the third quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company's stock worth $123,083,000 after purchasing an additional 516,569 shares in the last quarter. Pacer Advisors Inc. boosted its stake in shares of Arrowhead Pharmaceuticals by 11.6% in the fourth quarter. Pacer Advisors Inc. now owns 27,918 shares of the biotechnology company's stock valued at $525,000 after purchasing an additional 2,907 shares during the period. Finally, Franklin Resources Inc. grew its holdings in Arrowhead Pharmaceuticals by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 19,251 shares of the biotechnology company's stock valued at $373,000 after purchasing an additional 1,658 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Analysts Set New Price Targets

ARWR has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. StockNews.com upgraded Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, B. Riley reissued a "buy" rating and issued a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $41.44.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.